Mercaptamine bitartrate - Mylan

Drug Profile

Mercaptamine bitartrate - Mylan

Alternative Names: Cystagon; Cysteamine - Mylan/Orphan Europe; Cysteamine bitartrate

Latest Information Update: 10 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mylan
  • Developer Alphapharm; Mylan
  • Class Mercaptoethylamines; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Nephropathic cystinosis
  • Discontinued Unspecified

Most Recent Events

  • 09 Apr 2018 Mercaptamine bitartrate licensed to Recordati worldwide
  • 26 Oct 2017 Chemical structure information added
  • 31 Dec 2008 Mercaptamine bitartrate oral is still in phase II/III trials for Undefined indication in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top